Arnatar Therapeutics

Executive Summary

Arnatar Therapeutics is a private RNA medicine company founded in 2021 and headquartered in Cambridge, MA. The company is developing a proprietary dual-modality DARGER platform that enables both best-in-class siRNA (silencing) and first-in-class upregulating antisense oligonucleotides (ASOs). This platform aims to precisely silence disease-causing genes or restore missing protein expression, with initial focus on cardiometabolic, liver, CNS, and kidney diseases. Arnatar's approach offers the potential for broad therapeutic applications by addressing both gain-of-function and loss-of-function genetic drivers. As a private entity, Arnatar has not disclosed its total funding or valuation, and its current stage is preclinical, with no publicly disclosed pipeline candidates. The company's website and limited public information suggest it is still in the early research phase, likely advancing lead candidates toward IND-enabling studies.

Upcoming Catalysts (preview)

• Q4 2026Series A or equivalent financing round announcement60% success
• Q2 2027Preclinical proof-of-concept data in lead indication (e.g., cardiometabolic)40% success
• Q4 2027First IND filing or regulatory milestone20% success